Sandra Schenck1, Joachim Rosenbauer2, Martina Niewerth3, Jens Klotsche4, Kirsten Minden5, Tobias Schwarz6, Ivan Foeldvari7, Gerd Horneff8, Frank Weller-Heinemann9, Reinhard W Holl10, Angelika Thon11. 1. German Rheumatism Research Center Berlin, a Leibniz Institute, Berlin, Berlin, Germany. Electronic address: Sandra.Schenck@drfz.de. 2. Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Centre at Heinrich-Heine University Dusseldorf, Dusseldorf, Germany; German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany. 3. German Rheumatism Research Center Berlin, a Leibniz Institute, Berlin, Berlin, Germany. 4. German Rheumatism Research Center Berlin, a Leibniz Institute, Berlin, Berlin, Germany; Institute for Social Medicine, Epidemiology and Health Economics, Charité Universitätsmedizin, Berlin, Germany. 5. German Rheumatism Research Center Berlin, a Leibniz Institute, Berlin, Berlin, Germany; Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany. 6. Department of Pediatric Rheumatology, St. Josef-Stift, Sendenhorst, Germany. 7. Hamburg Centre for Rheumatology for Children and Adolescents, Clinical Center Eilbek, Germany. 8. Asklepios Clinic Sankt Augustin, Sankt Augustin, University Hospital of Cologne, Cologne, Germany. 9. Department of Pediatric Rheumatology, Prof.-Hess-Kinderklinik, Bremen, Germany. 10. Institute of Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Ulm, Germany. 11. Department of Pediatric Pneumology, Allergology and Neonatology, Children's Hospital, Medical School, Hanover, Germany.
Abstract
OBJECTIVES: To determine the prevalence of type 1 diabetes mellitus (T1D) in patients with juvenile idiopathic arthritis (JIA) and to characterize patients having both. STUDY DESIGN: Diabetes comorbidity was recorded in the National Pediatric Rheumatologic Database since 2012. Data from the North Rhine-Westphalian diabetes registry served as the reference population for the prevalence of diabetes in the general population. The National Pediatric Rheumatologic Database data were indirectly standardized for age and sex for comparison with the general population. The diabetes prevalence ratio was calculated using the Poisson regression model. RESULTS: The analysis included 12 269 patients with JIA. A total of 58 patients had comorbid T1D, and the diabetes prevalence was 0.5%. The mean age was 11.6 years at the time of documentation, and the mean disease duration was 4.2 years. Compared with the general population, the prevalence of diabetes in patients with JIA was significantly increased (prevalence ratio 1.76 [95% CI 1.34; 2.28], P < .001). The onset of diabetes in patients with JIA was earlier than that reported in the reference data. Sixty-three percent of patients developed T1D before JIA. On average, diabetes onset was 56 months before the onset of JIA. Patients who first developed JIA developed T1D on average 40 months later. The majority of patients had not received disease-modifying antirheumatic drugs before diabetes onset. CONCLUSIONS: T1D occurs more frequently in patients with JIA than in the general population. The likelihood of T1D occurrence appears to be slightly higher before JIA manifestation and without disease-modifying antirheumatic drug therapy after JIA onset.
OBJECTIVES: To determine the prevalence of type 1 diabetes mellitus (T1D) in patients with juvenile idiopathic arthritis (JIA) and to characterize patients having both. STUDY DESIGN:Diabetes comorbidity was recorded in the National Pediatric Rheumatologic Database since 2012. Data from the North Rhine-Westphalian diabetes registry served as the reference population for the prevalence of diabetes in the general population. The National Pediatric Rheumatologic Database data were indirectly standardized for age and sex for comparison with the general population. The diabetes prevalence ratio was calculated using the Poisson regression model. RESULTS: The analysis included 12 269 patients with JIA. A total of 58 patients had comorbid T1D, and the diabetes prevalence was 0.5%. The mean age was 11.6 years at the time of documentation, and the mean disease duration was 4.2 years. Compared with the general population, the prevalence of diabetes in patients with JIA was significantly increased (prevalence ratio 1.76 [95% CI 1.34; 2.28], P < .001). The onset of diabetes in patients with JIA was earlier than that reported in the reference data. Sixty-three percent of patients developed T1D before JIA. On average, diabetes onset was 56 months before the onset of JIA. Patients who first developed JIA developed T1D on average 40 months later. The majority of patients had not received disease-modifying antirheumatic drugs before diabetes onset. CONCLUSIONS: T1D occurs more frequently in patients with JIA than in the general population. The likelihood of T1D occurrence appears to be slightly higher before JIA manifestation and without disease-modifying antirheumatic drug therapy after JIA onset.
Authors: Maciej Szabłowski; Michał Andrzej Okruszko; Katarzyna Pochodowicz; Paweł Abramowicz; Jerzy Konstantynowicz; Artur Bossowski; Barbara Głowińska-Olszewska Journal: Rheumatol Int Date: 2022-01-08 Impact factor: 2.631